SEARCH:
Print

Bavarian Nordic Announces Activities Around the 2014 ASCO Annual Meeting

KVISTGAARD, Denmark, April 23, 2014 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the company will be present at the 2014 ASCO Annual Meeting in Chicago, IL from May 30 to June 3.

Bavarian Nordic will host a PROSTVAC update and reception for members of the investment community on Saturday, May 31, 2014 in Chicago, IL at 5 PM CDT.

Confirmed speakers and panelists include:

  • James L. Gulley, M.D., Ph.D. (NCI) 
  • Ravi A. Madan, M.D. (NCI) 
  • Larry Fong, M.D. (University of California San Francisco) 
  • Winald Gerritsen, M.D., Ph.D. (Radboud University Medical Centre Nijmegen) 
  • Alex Franzusoff, Ph.D. (SVP R&D, Bavarian Nordic)
  • James B. Breitmeyer, M.D., Ph.D. (President, Bavarian Nordic Inc.)

For registration and more information on this event, visit /asco2014.

Anders Hedegaard, President & CEO of Bavarian Nordic said: “We look forward to hosting this event which will highlight the potential of the Bavarian Nordic Cancer Immunotherapy pipeline. We welcome the opportunity to have these key opinion leaders join members of our management team to discuss the potential of PROSTVAC in treatment paradigm of men with prostate cancer, both alone and in combination with other agents.”

Bavarian Nordic will also be present at the conference with an exhibit, where visitors can learn more about PROSTVAC and the PROSPECT clinical trial - a global, randomized, double-blind, placebo-controlled Phase 3 study of PROSTVAC® in men with asymptomatic and minimally symptomatic metastatic, castration-resistant prostate cancer .

Beyond these activities, the company has submitted several scientific abstracts for presentation at ASCO, and will update the status of these once the embargo policies permit.

Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit www.bavarian-nordic.com.